Brought to you by 
PMV Pharmaceuticals raises $74mm through Series B round
22 Feb 2017
Executive Summary
PMV Pharmaceuticals Inc. raised $74mm through its Series B round from investors including co-leads Topspin Biotech Fund and investors with hedge fund Euclidean Capital, along with returning backers InterWest Partners, OrbiMed Advisors, and Osage University Partners. PMV is developing p53-targeted small-molecule cancer treatments, and will use the Series B proceeds to advance preclinical drug candidates into clinical trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PMV Pharmaceuticals raises $74mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice